LDFR
VRTX icon

Lehman & Derafelo Financial Resources’s Vertex Pharmaceuticals VRTX Stock Holding History

Lehman & Derafelo Financial Resources’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,001
Closed -$202K – 223
2021
Q2 		$202K Buy
+1,001
New +$209K 0.06% 122

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lehman & Derafelo Financial Resources's VRTX Position: Q3 2021 in Review

Lehman & Derafelo Financial Resources sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 1,001 shares — an estimated $202K sold.

Lehman & Derafelo Financial Resources first reported a position in VRTX in Q2 2021 and held it in 1 quarter. The position peaked at $202K in Q2 2021. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Lehman & Derafelo Financial Resources reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Lehman & Derafelo Financial Resources sold 1,001 Vertex Pharmaceuticals shares in Q3 2021, an estimated $202K.
  • Lehman & Derafelo Financial Resources first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Lehman & Derafelo Financial Resources's Vertex Pharmaceuticals position peaked at $202K in Q2 2021.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Lehman & Derafelo Financial Resources's 13F filing for Q3 2021, filed 28 Oct 2021.